Business
MCAP: Q3 2025 delivered 21% sales growth, 32% EBITA growth, and strong segment performance
MCAP: Q3 2025 delivered 21% sales growth, 32% EBITA growth, and strong segment performance
About this update from Medcap Ab
Q3 2025 saw 21% sales growth and 32% adjusted EBITA growth, with strong results across all segments and a robust balance sheet. Recent acquisitions and a positive M&A outlook support continued expansion.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.